General anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil)
This page covers all General anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GABA receptors (sevoflurane); mu-opioid receptor (remifentanil), D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor, Mu opioid receptor; norepinephrine transporter; serotonin transporter.
Targets
GABA receptors (sevoflurane); mu-opioid receptor (remifentanil) · D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor · Mu opioid receptor; norepinephrine transporter; serotonin transporter
Marketed (4)
- Sevoflurane and Remifentanil · University General Hospital of Patras · Anesthesiology
Sevoflurane is a volatile anesthetic that depresses the central nervous system, while remifentanil is a potent synthetic opioid that provides analgesia and enhances anesthesia. - Duragesic · Johnson & Johnson (Janssen Pharmaceutica) · Oncology
Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia. - Tramal® · Apsen Farmaceutica S.A. · Pain Management
Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and inhibits the reuptake of norepinephrine and serotonin to provide pain relief. - Tramadol HCl · Labopharm Inc. · Pain Management
Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.
Phase 3 pipeline (1)
- Tramadol 50 · Grünenthal GmbH · Pain Management
Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.
Patent intelligence
- synthetic opioid analgesic patent landscape — aggregated cliff calendar, attackable patents, originator estates